ArticleCureus2026
Spontaneous Tumor Lysis Syndrome Revealing Advanced Ovarian Carcinoma: From Oncologic Emergency to Complete Pathologic Response.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS) is an oncologic emergency characterized by metabolic abnormalities resulting from rapid tumor cell breakdown. It is most frequently observed following cytotoxic therapy in hematologic malignancies and is rarely encountered spontaneously in solid tumors. Spontaneous TLS associated with ovarian carcinoma remains exceptionally uncommon. A 53-year-old woman with no pertinent medical history presented with progressive abdominal distension, dyspnea, and oliguria. Laboratory evaluation demonstrated acute kidney injury with a serum creatinine of 4.09 mg/dL, accompanied by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, fulfilling the Cairo-Bishop criteria for clinical TLS. Computed tomography (CT) revealed massive ascites and a 16.2 × 15 × 15 cm pelvic mass without evidence of obstructive uropathy. Ascitic fluid cytology demonstrated metastatic carcinoma. Tumor markers showed a cancer antigen (CA)-125 level of 445 U/mL and a CA-125:carcinoembryonic antigen ratio greater than 25, strongly supporting a gynecologic primary malignancy. In the absence of recent chemotherapy or other precipitating factors, spontaneous TLS secondary to previously undiagnosed ovarian carcinoma was diagnosed. The patient was treated with aggressive intravenous hydration, rasburicase, electrolyte correction, and close multidisciplinary monitoring, resulting in rapid normalization of metabolic abnormalities and recovery of renal function without dialysis. Following stabilization, the patient underwent neoadjuvant carboplatin-paclitaxel chemotherapy followed by interval cytoreductive surgery. Histopathologic examination demonstrated a complete pathologic response, with no residual invasive carcinoma. Follow-up positron emission tomography/CT imaging showed no evidence of residual or metastatic disease, and CA-125 normalized to 5.2 U/mL. This case highlights spontaneous TLS as a rare initial manifestation of advanced ovarian carcinoma and emphasizes the importance of early recognition and prompt intervention. Timely management may reverse life-threatening metabolic complications, facilitate definitive oncologic treatment, and result in favorable long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.